CARDIZEM LA Drug Patent Profile

When do Cardizem La patents expire, and when can generic versions of Cardizem La launch?

Cardizem La is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in CARDIZEM LA is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cardizem La

A generic version of CARDIZEM LA was approved as diltiazem hydrochloride by TEVA on May 31^st, 1995.

Summary for CARDIZEM LA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	116
Clinical Trials:	10
Patent Applications:	3,360
Drug Prices:	Drug price information for CARDIZEM LA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CARDIZEM LA
What excipients (inactive ingredients) are in CARDIZEM LA?	CARDIZEM LA excipients list
DailyMed Link:	CARDIZEM LA at DailyMed

See drug prices for CARDIZEM LA

See drug sales revenues for CARDIZEM LA

Recent Clinical Trials for CARDIZEM LA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Early Phase 1
CAMC Health System	Phase 4
University of South Florida	N/A

See all CARDIZEM LA clinical trials

Pharmacology for CARDIZEM LA

Drug Class	Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 3A4 Inhibitors

Paragraph IV (Patent) Challenges for CARDIZEM LA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CARDIZEM LA	Extended-release Tablets	diltiazem hydrochloride	120 mg, 180 mg, 240 mg, 300 mg and 360 mg	021392	1	2005-08-30
CARDIZEM LA	Extended-release Tablets	diltiazem hydrochloride	420 mg	021392	1	2005-04-25

US Patents and Regulatory Information for CARDIZEM LA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-001	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-004	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-002	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-003	Feb 6, 2003	AB	RX	Yes	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-006	Feb 6, 2003	AB	RX	Yes	Yes

Expired US Patents for CARDIZEM LA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-004	Feb 6, 2003
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-006	Feb 6, 2003
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-003	Feb 6, 2003
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-001	Feb 6, 2003
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-003	Feb 6, 2003

International Patents for CARDIZEM LA

See the table below for patents covering CARDIZEM LA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	293438
World Intellectual Property Organization (WIPO)	0141744
Japan	3725474
European Patent Office	0591424	DILTIAZEM SE PRESENTANT SOUS UNE FORME A LIBERATION PROLONGEE (EXTENDED-RELEASE FORM OF DILTIAZEM)
Austria	430561

Market Dynamics and Financial Trajectory for CARDIZEM LA

Last updated: January 14, 2026

Executive Summary

CARDIZEM LA (diltiazem hydrochloride extended-release) is a calcium channel blocker primarily used in the management of hypertension, angina pectoris, and certain arrhythmias. Its market landscape is shaped by evolving cardiovascular disease prevalence, competitive pharmaceutical innovations, regulatory frameworks, and payer policies. This report analyzes the current market dynamics, revenue forecasts, strategic drivers, and potential challenges influencing CARDIZEM LA's financial trajectory. As the global cardiovascular market approaches a valuation of USD 70 billion by 2030 [1], understanding CARDIZEM LA's position is vital for stakeholders aiming to optimize investment, R&D, and commercialization strategies.

---

1. Market Overview and Current Position

1.1. Product Profile

Attribute	Details
Generic Name	Diltiazem Hydrochloride Extended-Release
Brand Name	CARDIZEM LA
Therapeutic Class	Calcium Channel Blocker
Approved Indications	Hypertension, Chronic Stable Angina, Certain Arrhythmias
Formulation	Tablets, Extended-release
Sale Launch	FDA approval in 1990; marketed by Pfizer (original)

1.2. Market Penetration & Revenue

Region	Market Share (2022)	Estimated Revenue (USD, 2022)	Notes
North America	40%	~$600 million	Dominant due to high prevalence of hypertension and robust healthcare infrastructure
Europe	25%	~$375 million	Competitive landscape, discount generics available
Asia-Pacific	20%	~$300 million	Growing awareness, expanding healthcare coverage
Rest of World	15%	~$225 million	Emerging markets, increasing cardiovascular disease burden
Total		~USD 1.5 billion	-

1.3. Key Market Players

Company	Product/Brand	Market Share (%)	Notes
Pfizer	CARDIZEM LA	55%	Original manufacturer; patent expiry in 2008
Teva Pharmaceuticals	Diltiazem Extended-Release	20%	Leading generics provider
Others (Amneal, Mylan)	Various generics	25%	Growing market competition

---

2. Market Drivers Influencing CARDIZEM LA’s Financial Trajectory

2.1. Growing Burden of Cardiovascular Diseases (CVD)

According to WHO, CVD accounts for approximately 17.9 million deaths annually [2]. The aging population, sedentary lifestyles, and increasing hypertension prevalence amplify demand for antihypertensives like CARDIZEM LA. The global hypertensive population is projected to reach 1.5 billion by 2025, fueling sustained demand.

2.2. Patent Expiry and Generic Competition

While Pfizer’s patent protection ended in 2008, the advent of high-quality generics from companies like Teva and Mylan has significantly compressed margins. Price erosion trends:

Year	Price Decline (%)	Comments
2010	40%	Introduction of generics
2015	30%	Market saturation
2020	25%	Continued competition

Implication: Revenue from branded CARDIZEM LA has plateaued; future growth depends on volume increases and emerging markets.

2.3. Regulatory Policies & Reimbursement Landscape

In US, Medicare and Medicaid reimbursement policies favor generics, limiting branded drug profitability. Conversely, countries with evolving healthcare systems (e.g., India, Brazil) offer expanding markets with less price regulation.

2.4. Clinical Guidelines and Prescribing Trends

Current guidelines recommend calcium channel blockers for hypertension management:

Organization	Guidelines Preference	Notes
ACC/AHA [3]	First-line options	Particularly in African-American populations
ESC [4]	Additive therapy	For resistant hypertension
WHO	Essential medicine list	CARDIZEM LA listed

Prescribing habits are shifting towards cost-effective generic options, but CARDIZEM LA retains preference in certain clinical scenarios.

2.5. Technological and Formulation Innovations

Development of novel formulations (e.g., bioequivalent extended-release) enhances adherence, expanding market adoption. Additionally, combination therapies including CARDIZEM LA with other antihypertensives are gaining traction.

---

3. Financial Forecasting & Market Trajectory

3.1. Historical Revenue Trends

Year	Revenue (USD Million)	Comment
2010	1,000	Peak before generic entry
2015	700	Impact of patent expiry, market saturation
2020	650	Stabilization with minor fluctuations

3.2. Projected Revenue (2023–2030)

Year	Estimated Revenue (USD Million)	Growth Rate (%)	Assumptions
2023	700	7.7%	Continued volume growth in emerging markets
2024	750	7.1%	Gains from formulary inclusion and new formulations
2025	800	6.7%	Increasing prevalence, price stabilization
2026	850	6.3%	Market expansion, new licensing agreements
2027	900	5.9%	Mature market phase
2028	950	5.6%	Slight price inflation
2029	1,000	5.3%	Steady demand
2030	1,050	5.0%	Market maturity

Compound Annual Growth Rate (CAGR): ~5.8% over 2023–2030.

3.3. Risk Factors & Challenges

Risk Factor	Impact	Mitigation Strategies
Patent and regulatory barriers	Limited innovation, commoditization	Focus on formulation improvements, combination therapies
Market saturation	Slower revenue growth	Expand in emerging markets, formulary strategies
Price erosion from generics	Reduced profit margins	Cost optimization, value-added services
Shifts in clinical guidelines	Potential preference for alternative therapies	Evidence generation, clinical trials
Reimbursement policies	Impact on drug affordability and access	Policy engagement, lobbying

---

4. Competitive Landscape and Strategic Positioning

Competitor	Focus Areas	Strengths	Challenges
Pfizer	Original patent holder, global reach	Brand equity, extensive R&D	Patent expiry, generic competition
Teva	Large generics portfolio	Cost leadership, global supply chain	Market share pressures, patent challenges
Mylan (now part of Viatris)	Diversified portfolio	Price competitiveness	Regulatory compliance, market differentiation
Local/Niche Players	Regional generics, biosimilars	Market accessibility	Limited global reach, quality concerns

Strategic recommendations: Investing in formulation differentiation, leveraging expanding markets, and engaging in clinical research to support new indications.

---

5. Policy & Regulatory Insights Impacting Future Growth

Policy Area	Impact	Key Regulations/Policies
Patent Law	Defines market exclusivity periods	US Hatch-Waxman Act, TRIPS Agreement
Reimbursement Policies	Influences drug pricing and access	CMS (US), National Health Insurance schemes
Quality Standards	Ensures safety and efficacy	FDA, EMA, WHO standards
Import/Export Regulations	Affect supply chain reliability	Customs tariffs, trade agreements
Public Health Initiatives	Drive demand for essential medications	WHO's Essential Medicines List, national policies

---

6. Comparative Analysis: CARDIZEM LA vs. Similar Agents

Parameter	CARDIZEM LA	Diltiazem Immediate-Release (IR)	Amlodipine	Verapamil
Formulation	Extended-release, once daily	Multiple doses per day	Once daily	Multiple doses per day
Indications	Hypertension, angina, arrhythmias	Same	Same	Same
Onset of Action	1-2 hours	Faster	Similar	Similar
Duration of Action	Up to 24 hours	Shorter	Up to 24 hours	Up to 24 hours
Cost (USD per unit)	~$0.50 (generics)	~$0.30	~$0.25	~$0.35
Patient Compliance	Higher (once daily)	Lower (multiple doses)	Moderate	Moderate

---

7. Future Opportunities and Innovations

7.1. Formulation & Delivery Advances

• Development of tamper-proof, user-friendly formulations.
• Fixed-dose combinations (FDCs) with other antihypertensives.
• Long-acting injectables or transdermal patches.

7.2. Personalized Medicine

• Pharmacogenomic profiling to optimize therapy.
• Biomarkers predicting responsiveness.

7.3. Expansion into Emerging Markets

• Tailored marketing strategies.
• Local manufacturing to reduce costs.

7.4. R&D in Novel Indications

• Exploring cardioprotective roles beyond hypertension.
• Investigating neuroprotective potentials.

---

8. Key Takeaways

• Market Maturity & Competition: Post-patent expiry, CARDIZEM LA faces aggressive generic competition, compelling reliance on volume growth and emerging markets.

• Growth Drivers: Rising global CVD burden, formulary inclusions, improved formulations, and expanding healthcare infrastructure underpin future revenue prospects.

• Revenue Outlook: CAGR of approximately 5.8% over 2023–2030 suggests stable long-term growth, with total revenues potentially surpassing USD 1.05 billion by 2030.

• Challenges & Risks: Patent expiration impacts, pricing pressures, regulatory changes, and evolving clinical guidelines necessitate adaptive strategies.

• Opportunities: Innovation in delivery systems, strategic positioning in emerging markets, and combination therapies offer avenues for growth.

---

References

[1] Market Research Future. "Global Cardiovascular Disease Market Forecast to 2030." 2022.

[2] WHO. "Cardiovascular Diseases (CVDs)." 2021.

[3] American College of Cardiology/American Heart Association. "2017 Hypertension Guidelines." JACC, 2018.

[4] European Society of Cardiology. "Hypertension Guidelines," 2018.

---

FAQs

Q1: What are the primary factors influencing the decline in CARDIZEM LA revenues?
A: Patent expiration, intensified generic competition, price erosion, and shifting clinical guidelines favoring cost-effective alternatives.

Q2: How does CARDIZEM LA compare to other antihypertensives in terms of patient adherence?
A: Its extended-release formulation supports once-daily dosing, improving adherence relative to immediate-release formulations requiring multiple daily doses.

Q3: What strategies can manufacturers adopt to sustain profitability?
A: Developing novel formulations, entering emerging markets, fostering strategic alliances, and pursuing new indications.

Q4: What role do regulatory policies play in shaping market opportunities?
A: Policies influence pricing, reimbursement, patent protections, and market access; proactive engagement ensures alignment with evolving regulations.

Q5: Are there upcoming innovations that could redefine CARDIZEM LA’s market position?
A: Yes, advancements in drug delivery systems, fixed-dose combination therapies, and personalized medicine approaches could enhance long-term competitiveness.

---

In conclusion, while CARDIZEM LA faces challenges from generic competition and market saturation, strategic innovation, market expansion, and adaptation to healthcare policy trends can sustain its financial trajectory in the evolving cardiovascular therapeutics landscape.